Telehealth discussions about end-of-life care for patients with high grade glioma
Official title: Early Telehealth Visits for Discussion of Advanced Directives for Patients Newly Diagnosed With High Grade Glioma: Impact on Patient Care and Satisfaction
Run by University of Rochester · NCT04543201 · Data updated 2026-11-12
This study is trying to see if telehealth visits can help patients with high grade glioma and their families have important conversations about end-of-life care planning.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University of Rochester Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Rochester, New York) |
| Status | Recruiting |
| Started | October 8, 2021 |
| Main results expected | July 31, 2026 |
| Study ends | July 31, 2026 |
| Registry record updated | December 18, 2025 |
| Trial ID | NCT04543201 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are English-speaking patients with a new diagnosis of WHO grade III or IV glioma within four months of consent.
✕Probably not a fit
Patients with severe cognitive dysfunction or aphasia that prevents them from discussing advanced care planning will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to facilitate early discussions about advance care planning for patients newly diagnosed with high grade glioma through telehealth visits. Patients will receive a pre-visit educational guide and participate in a structured visit with trained providers using a checklist to ensure comprehensive discussions. The intervention will include family members or caregivers to support the patient during these critical conversations. The study will assess patient and caregiver perspectives, knowledge, satisfaction, and anxiety levels following the visit.
Why it matters
Potential benefit: If successful, this approach could improve the quality of end-of-life care for patients with high grade glioma by ensuring their wishes are documented and respected.
How similar studies have gone: While telehealth interventions for advance care planning are emerging, this specific structured approach for high grade glioma patients is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * New pathologic diagnosis of WHO grade III or IV glioma within four months of consent * English speaking Exclusion Criteria: * Severe cognitive dysfunction or aphasia precluding discussion of advanced care planning issues
Where it's running
-
University of Rochester
Rochester, New York, United States Recruiting
Study contacts
- Principal investigator: Sara Hardy, MD — University of Rochester
- Study coordinator: Sara Hardy, MD
- Email: Sara_Hardy@URMC.rochester.edu
- Phone: 585-273-4096
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.